MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It utilizes its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy and dilated cardiomyopathy.  The company was founded in 2012 and is headquartered in Brisbane, California.

Bristol-Myers

Pharma giant Bristol-Myers Squibb Co (NYSE: BMY) is bulking up, as the company announced a multi-billion dollar deal to buy cardio-focused biopharma Myokardia Inc (NASDAQ: MYOK). Deal Terms: Bristol-Myers Squibb announced Monday a definitive agreement to buy Myokardia for $225 per share, or $13.1 billion, in cash.

Bristol-Myers Squibb Beefs Up Cardiology Franchise With $13.1B Deal To Buy Myokardia

In an announcement on Monday, Bristol Myers Squibb Co (NYSE: BMY) said it will invest £10 billion to acquire MyoKardia Inc (Nasdaq: MYOK). The deal, it added, will help it expand its footprint in the heart drugs business and minimise reliance on cancer treatments.

Bristol Myers to acquire MyoKardia for £10 billion

SAN DIEGO, Oct. 5, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of MyoKardia, Inc. ("MyoKardia" or the "Company") (NASDAQ: MYOK) breached their fiduciary duties in connection with the proposed sale of the...

(MYOK) Alert: Johnson Fistel Investigates Proposed Sale of MyoKardia; Is $225 a Fair Price?

Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, as it seeks to reduce some of its dependence on cancer drugs.

Bristol Myers to buy heart drug developer MyoKardia for about $13 billion

Shares of MyoKardia Inc. MYOK, -0.36% soared 57% toward a record high in premarket trading Monday, after the biotechnology company confirmed that it agreed to be bought out by Bristol Myers Squibb Co. BMY, -1.83% in a deal valued at $13.1 billion in cash. Bristol Myers' stock slipped 0.5% ahead of the open.

MyoKardia's stock soars toward a record after $13 billion buyout deal with Bristol Myers

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and is anticipated to close during the fourth quarter of 2020. MyoKardia is a clinical-stage biopharmaceutical company discove

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

BRISBANE, Calif., Sept.  09, 2020  (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere. Danicamtiv is MyoKardia’s most advanced clinical candidate being developed for the treatment of genetic dilated cardiomyopathy (DCM) and other targeted populations with conditions of reduced systolic function.

MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy

EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet

MyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Allogene Therapeutics Inc

DraftKings

Plug Power

United Therapeutics

Acceleron Pharma

It's not uncommon for stocks that have significantly outperformed for several months to take a breather.

7 Best Stocks to Buy Now for More Red-Hot Returns

Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM

MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China

Virtual Analyst and Investor Event to Review Data Planned for 8:00 a.m. EDT on August 31 Virtual Analyst and Investor Event to Review Data Planned for 8:00 a.m. EDT on August 31

Data from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020

BRISBANE, Calif., Aug.  05, 2020  (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Jake Bauer, Chief Business Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 3:30 p.m. ET.

MyoKardia to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

MyoKardia, Inc. (MYOK) CEO Tassos Gianakakos on Q2 2020 Results - Earnings Call Transcript

BRISBANE, Calif., Aug.  04, 2020  (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020.

MyoKardia Reports Second Quarter 2020 Financial Results

VALOR-HCM Designed to Generate Direct Evidence of Improved Outcomes for People with HCM by Reducing the Need for Invasive Septal Reduction Therapy VALOR-HCM Designed to Generate Direct Evidence of Improved Outcomes for People with HCM by Reducing the Need for Invasive Septal Reduction Therapy

CORRECTION: MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

BRISBANE, Calif., July  28, 2020  (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and operating results on Tuesday, August 4, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT). 

MyoKardia to Report Second Quarter 2020 Financial Results on Tuesday, August 4, 2020

BRISBANE, Calif., July  23, 2020  (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM).  The FDA's Breakthrough Therapy Designation is intended to expedite the development and review of a drug candidate that is planned for use to treat a serious or life-threatening disease or condition when clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. 

MyoKardia Announces Receipt of Breakthrough Therapy Designation from FDA for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic Cardiomyopathy

BRISBANE, Calif., July  06, 2020  (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Ms. Waynick joins MyoKardia from UCB, Inc., bringing more than 25 years of domestic and international legal and business expertise in the healthcare and life-science industry.

MyoKardia Announces Appointment of Denelle J. Waynick as General Counsel and Corporate Secretary

MyoKardia's Positive Data And Other News: The Good, Bad And Ugly Of Biopharma

Danicamtiv was Well Tolerated;  Demonstrated Improvements in Cardiac Contractility and Preserved Diastolic Function in Patients with Stable Heart Failure with Reduced Ejection Fraction

MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC’s HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure

-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 --   BRISBANE, Calif., June  19, 2020  (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that data from the company’s Phase 2a multiple-ascending dose study of danicamtiv (formerly MYK-491) in patients with chronic heart failure with reduced ejection fraction (HFrEF) will be presented in a late-breaker session at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries ( HFA Discoveries ) event. Danicamtiv is MyoKardia’s lead activator candidate designed to increase the contractility of the heart (systolic function) with minimal or no effect on myocardial relaxation and compliance (diastolic function) by acting directly on the proteins in the heart muscle responsible for contraction.

MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries

BRISBANE, Calif., June  16, 2020  (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the virtual BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23rd, 2020 at 10:30 a.m. ET.

MyoKardia to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference

Solid phase 3 data from MyoKardia’s lead drug candidate drove share gains.

Why MyoKardia Shares Rose 62.8% in May

A phase 3 victory for MyoKardia’s lead drug candidate may lead to more wins down the road.

News for MyoKardia Stock (MYOK)